UK-315716/UK-240455. Pfizer.

Abstract	Pfizer is developing the atropoisomeric quinoxalinediones, UK-315716 and UK-240255, from a series of NMDA/glycine antagonists for the potential treatment of stroke. Both are compounds are undergoing clinical trials. UK-315716 has improved aqueous solubility and in vivo efficacy over UK-240455, and a lower projected clinical dose of 200 mg compared to 500 mg with UK-240455.
Authors	A M Capelli, F Micheli
Journal	Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 2 Issue 12 Pg. 1737-9 (Dec 2001) ISSN: 1472-4472 [Print] England
PMID	11892937 (Publication Type: Journal Article, Review)
Chemical References	Neuroprotective Agents Quinoxalines Receptors, Glycine Receptors, N-Methyl-D-Aspartate UK240455 UK315716
Topics	Animals Clinical Trials, Phase I as Topic Humans Neuroprotective Agents (pharmacology, therapeutic use) Quinoxalines (pharmacology, therapeutic use) Receptors, Glycine (antagonists & inhibitors) Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors) Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!